Want to see TSHA full AI Analyst Report?
Taysha Gene Therapies (TSHA) Income Statement
Taysha Gene Therapies Income Statement
Last quarter (Q2 2026), Taysha Gene Therapies's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Taysha Gene Therapies's net income was $-46.64M. See Taysha Gene Therapies’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 9.77M | $ 8.33M | $ 15.45M | $ 2.50M | $ 0.00 | |
| $ 9.77M | $ 8.33M | $ 15.45M | $ 15.00K | $ 0.00 | |
| $ 120.27M | $ 99.79M | $ 87.89M | $ 126.04M | $ 173.27M | |
| Depreciation and Amortization | $ 1.15M | $ 1.25M | $ 1.37M | $ 1.17M | $ 492.00K |
| $ -107.79M | $ -87.95M | $ -105.20M | $ -161.04M | $ -172.60M | |
| $ -110.50M | $ -91.46M | $ -72.44M | $ -126.03M | $ -173.27M | |
| $ 1.50M | $ 2.16M | $ -39.13M | $ -39.99M | $ -1.26M | |
| $ -109.00M | $ -89.30M | $ -111.57M | $ -166.01M | $ -174.52M | |
| $ -109.00M | $ -89.30M | $ -111.57M | $ -166.01M | $ -174.52M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.34 | $ -0.36 | $ -0.96 | $ -3.78 | $ -4.64 |
| Diluted EPS | $ -0.34 | $ -0.36 | $ -0.96 | $ -3.78 | $ -4.64 |
| Weighted Average Shares Outstanding | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M |
| Weighted Average Shares Outstanding (Diluted) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M |
Currency in USD
